| 11.49 0.74 (6.88%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.01  |
1-year : | 16.37 |
| Resists | First : | 11.99 |
Second : | 14.01 |
| Pivot price | 9.67 |
|||
| Supports | First : | 9 |
Second : | 7.15 |
| MAs | MA(5) : | 10.59 |
MA(20) : | 9.38 |
| MA(100) : | 9.17 |
MA(250) : | 0 | |
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 86.8 |
D(3) : | 85.8 |
| RSI | RSI(14): 65.8 |
|||
| 52-week | High : | 21.5 | Low : | 5.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STRO ] has closed above the upper band by 3.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 26.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.01 - 12.04 | 12.04 - 12.08 |
| Low: | 10.63 - 10.67 | 10.67 - 10.72 |
| Close: | 11.42 - 11.48 | 11.48 - 11.55 |
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Wed, 24 Dec 2025
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 85.9% in December - MarketBeat
Mon, 22 Dec 2025
STRO: HC Wainwright Raises Price Target by 400% Today | STRO Sto - GuruFocus
Mon, 22 Dec 2025
HC Wainwright & Co. Maintains Sutro Biopharma (STRO) Neutral Recommendation - Nasdaq
Thu, 18 Dec 2025
Sutro Biopharma Regains Nasdaq Listing Compliance - The Globe and Mail
Wed, 17 Dec 2025
Sutro Biopharma Regains Nasdaq Compliance Following Reverse Stock Split - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 6.1e+006 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 339 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2899e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -205.2 % |
| Operating Margin | -401.4 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.0565e+008 % |
| Gross Profit (p.s.) | 8.51 |
| Sales Per Share | 500 |
| EBITDA (p.s.) | 8.91173e+007 |
| Qtrly Earnings Growth | -26 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -223 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.02 |
| Price to Cash Flow | -1.82 |
| Dividend | 0 |
| Forward Dividend | 397740 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|